First-in-Human Evaluation of Site-Specifically Labeled ⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.